# Zoetis Inc. (ZTS)

Source: https://www.quantisnow.com/company/ZTS
Generated: 2026-11-11T13:44:03.196Z

- Ticker: ZTS
- Exchange: NYSE
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2013
- SEC CIK: 0001555280
- Website: zoetis.com

## About

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, blood glucose monitors, and laboratory services; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

## Latest ZTS news and filings

- 2026-11-11 12:30 UTC [Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis](https://www.quantisnow.com/insight/zoetis-receives-usda-license-for-cytopoint-plus-the-first-and-6785179)
- 2026-11-10 12:30 UTC [Conference Announcement] [Zoetis to Participate in the Jefferies Global Healthcare Conference in London](https://www.quantisnow.com/insight/zoetis-to-participate-in-the-jefferies-global-healthcare-conference-in-6782825)
- 2026-11-05 16:40 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Zoetis Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-zoetis-inc-6775357)
- 2026-11-05 12:05 UTC [SEC Form 8-K] [Zoetis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/zoetis-inc-filed-sec-form-8-k-results-of-operations-and-6774501)
- 2026-11-05 12:00 UTC [Earnings] [Zoetis Announces Third Quarter 2026 Results; Highlights Progress Advancing Innovation Across Diversified Portfolio and Narrows Full Year 2026 Revenue Guidance, Raises Full Year 2026 Adjusted EPS Guidance](https://www.quantisnow.com/insight/zoetis-announces-third-quarter-2026-results-highlights-progress-advancing-innovation-6774382)
- 2026-11-03 21:36 UTC [SEC Form 4] [Director Stetter Mark was granted 6 phantom stock units (SEC Form 4)](https://www.quantisnow.com/insight/director-stetter-mark-was-granted-6-phantom-stock-units-sec-6770178)
- 2026-10-20 20:42 UTC [Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment](https://www.quantisnow.com/insight/zoetis-receives-fda-approval-for-convenia-rtu-for-dogs-cefovecin-6752357)
- 2026-10-20 11:50 UTC [Analyst Downgrade] [Zoetis downgraded by Jefferies with a new price target](https://www.quantisnow.com/insight/zoetis-downgraded-by-jefferies-with-a-new-price-target-6751459)
- 2026-10-16 12:49 UTC [Analyst Coverage Initiated] [Goldman initiated coverage on Zoetis with a new price target](https://www.quantisnow.com/insight/goldman-initiated-coverage-on-zoetis-with-a-new-price-target-6748806)
- 2026-10-14 01:13 UTC [SEC Form 4] [SEC Form 4 filed by Zoetis Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-zoetis-inc-6745656)
- 2026-10-14 01:13 UTC [SEC Form 4] [SEC Form 4 filed by Zoetis Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-zoetis-inc-6745655)
- 2026-10-14 01:13 UTC [SEC Form 4] [SEC Form 4 filed by Zoetis Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-zoetis-inc-6745654)
- 2026-10-14 01:13 UTC [SEC Form 4] [SEC Form 4 filed by Zoetis Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-zoetis-inc-6745653)
- 2026-10-14 01:13 UTC [SEC Form 4] [SEC Form 4 filed by Zoetis Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-zoetis-inc-6745651)
- 2026-10-14 01:13 UTC [SEC Form 4] [SEC Form 4 filed by Zoetis Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-zoetis-inc-6745650)
- 2026-10-14 01:13 UTC [SEC Form 4] [SEC Form 4 filed by Zoetis Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-zoetis-inc-6745649)
- 2026-10-14 01:13 UTC [SEC Form 4] [SEC Form 4 filed by Zoetis Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-zoetis-inc-6745648)
- 2026-10-13 11:32 UTC [SEC Form 8-K] [SEC Form 8-K filed by Zoetis Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-zoetis-inc-6744142)
- 2026-10-13 11:30 UTC [Leadership Update] [Zoetis Appoints Iris Knobloch to its Board of Directors](https://www.quantisnow.com/insight/zoetis-appoints-iris-knobloch-to-its-board-of-directors-6744102)
- 2026-10-08 20:16 UTC [SEC Form 8-K] [SEC Form 8-K filed by Zoetis Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-zoetis-inc-6741855)
- 2026-10-08 20:15 UTC [Dividends] [Zoetis Declares Fourth Quarter 2026 Dividend](https://www.quantisnow.com/insight/zoetis-declares-fourth-quarter-2026-dividend-6741815)
- 2026-10-06 11:30 UTC [New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1](https://www.quantisnow.com/insight/new-peer-reviewed-publication-on-laboratory-study-that-demonstrated-simparica-trio-6738097)
- 2026-10-02 20:43 UTC [SEC Form 4] [Executive Vice President Fuller Julie converted options into 799 shares and covered exercise/tax liability with 274 shares, increasing direct ownership by 49% to 1,588 units (SEC Form 4)](https://www.quantisnow.com/insight/executive-vice-president-fuller-julie-converted-options-into-799-shares-6734979)
- 2026-09-24 11:30 UTC [Earnings Date] [Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results](https://www.quantisnow.com/insight/zoetis-to-host-webcast-and-conference-call-on-third-quarter-6724788)
- 2026-09-18 21:56 UTC [SEC Form 4] [SEC Form 4 filed by Director Stetter Mark](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-stetter-mark-6720898)
- 2026-09-02 20:34 UTC [SEC Form 4] [SEC Form 4 filed by EVP,  CFO & COO Saccaro James](https://www.quantisnow.com/insight/sec-form-4-filed-by-evp-cfo-coo-saccaro-james-6703448)
- 2026-09-02 11:30 UTC [Conference Announcement] [Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference](https://www.quantisnow.com/insight/zoetis-to-participate-in-the-morgan-stanley-24th-annual-global-6702280)
- 2026-08-24 20:32 UTC [SEC Form 3] [New insider Saccaro James claimed no ownership of stock in the company (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-saccaro-james-claimed-no-ownership-of-stock-in-6692906)
- 2026-08-13 19:51 UTC [Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies](https://www.quantisnow.com/insight/zoetis-receives-emergency-use-authorization-for-simparica-trio-sarolaner-moxidectin-6680075)
- 2026-08-11 20:52 UTC [SEC Form 4] [Director Damelio Frank A gifted 6,650 shares, decreasing direct ownership by 31% to 14,808 units (SEC Form 4)](https://www.quantisnow.com/insight/director-damelio-frank-a-gifted-6650-shares-decreasing-direct-ownership-6676323)
- 2026-08-06 20:17 UTC [SEC Form 8-K] [SEC Form 8-K filed by Zoetis Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-zoetis-inc-6669327)
- 2026-08-06 18:32 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Zoetis Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-zoetis-inc-6668404)
- 2026-08-06 16:04 UTC [Analyst Downgrade] [Zoetis downgraded by William Blair](https://www.quantisnow.com/insight/zoetis-downgraded-by-william-blair-6668258)
- 2026-08-06 11:06 UTC [SEC Form 8-K] [Zoetis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/zoetis-inc-filed-sec-form-8-k-results-of-operations-and-6667194)
- 2026-08-06 11:00 UTC [Earnings Date] [Zoetis Announces Second Quarter 2026 Results](https://www.quantisnow.com/insight/zoetis-announces-second-quarter-2026-results-6667035)
- 2026-08-06 11:00 UTC [Leadership Update] [Zoetis Appoints Jay Saccaro as Chief Financial Officer and Chief Operating Officer](https://www.quantisnow.com/insight/zoetis-appoints-jay-saccaro-as-chief-financial-officer-and-chief-6667030)
- 2026-07-22 11:30 UTC [Zoetis Launches Portela® (relfovetmab) in Canada and the European Union](https://www.quantisnow.com/insight/zoetis-launches-portela-relfovetmab-in-canada-and-the-european-union-6644592)
- 2026-07-15 12:30 UTC [Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union](https://www.quantisnow.com/insight/zoetis-launches-lenivia-izenivetmab-injection-in-canada-and-the-european-6637703)
- 2026-07-14 21:48 UTC [SEC Form 4] [SEC Form 4 filed by Executive Vice President Sarbaugh Keith](https://www.quantisnow.com/insight/sec-form-4-filed-by-executive-vice-president-sarbaugh-keith-6637190)
- 2026-07-14 21:48 UTC [SEC Form 4] [SEC Form 4 filed by Chief Executive Officer Peck Kristin C](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-executive-officer-peck-kristin-6637189)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ZTS
- Earnings history: https://www.quantisnow.com/earnings/ZTS
- Dividend history: https://www.quantisnow.com/dividends/ZTS
- Insider transactions: https://www.quantisnow.com/insiders/ZTS
- Options chain: https://www.quantisnow.com/options/ZTS
- SEC 8-K filings only: https://www.quantisnow.com/company/ZTS/8-k
- RSS and alerts for ZTS: https://www.quantisnow.com/docs/rss-feeds.md